Laura Martinez-Prat is Scientific and Clinical Affairs Manager for Autoimmunity at Werfen. With more than 12 years dedicated to autoimmunity research, Laura is widely regarded for her expertise in advancing innovative diagnostics that improve the detection and management of autoimmune diseases. Her extensive background encompasses both translational and clinical research, as well as the development and implementation of advanced diagnostic solutions that are transforming the landscape of autoimmune patient care.
In her current role at Werfen, Laura spearheads scientific initiatives and collaborative research projects with renowned institutions and research centers worldwide. She is dedicated to advancing the understanding and application of autoantibodies as critical biomarkers for the diagnosis, prognosis, and management of autoimmune diseases, including idiopathic inflammatory myopathies. She’s passionate about advancing patient-centered solutions that improve outcomes and transform clinical practice.
Manuel Lubinus, PhD, is the Chief Science Officer and Director of the “Right Now Research” initiative at Myositis Support and Understanding (MSU), a patient-led nonprofit advancing research, advocacy, education, and support for people affected by myositis.
Diagnosed with Inclusion Body Myositis (IBM) in 2019, Dr. Lubinus turned his lived experience with this rare muscle-weakening condition into a central mission: accelerating patient-centered research and improving outcomes for the myositis community.
He holds a doctorate in immunology and an MBA, with over 25 years of combined experience in bench research, scientific communication, and pharmaceutical/medical device marketing management. After his diagnosis, he retired from corporate roles to dedicate his efforts full-time to myositis advocacy, research strategy, and collaborative scientific initiatives.
In his work with MSU, Dr. Lubinus leads cross-disciplinary partnerships with investigators in the U.S. and internationally, integrates patient perspectives into research planning, and represents MSU in broader scientific collaborations. His approach emphasizes patient-driven research priorities, aiming to ensure that clinical studies, registries, and treatment development directly reflect the lived experiences and needs of those with myositis.
Please be advised that you are now leaving the Werfen Website. Links are provided as a convenience and for informational purposes only. Werfen bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.